Literature DB >> 19670458

How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death.

James S Michaelson1, L Leon Chen, Melvin J Silverstein, Martin C Mihm, Arthur J Sober, Kenneth K Tanabe, Barbara L Smith, Jerry Younger.   

Abstract

BACKGROUND: : It has long been appreciated that tumor size, lymph node status, and patient survival are related qualities, although how to isolate their interactions has not been obvious, nor has it been obvious how to integrate tumor size and lymph node status into predictions of the risk of death for individual patients.
METHODS: : The authors describe a mathematical method, the binary-biological model of cancer metastasis, based on the spread of cancer cells, in which the equations capture the relations between tumor size, lymph node status, and cancer lethality.
RESULTS: : For melanoma, renal cell carcinoma, and breast carcinoma, the relation between tumor size and the risk of cancer death was captured by the SizeOnly equation. For melanoma and breast carcinoma, the relation between tumor size and the presence of cancer in the lymph nodes was captured by using the NodalSizeOnly equation. For lymph node-negative melanoma and breast carcinoma, the relation between tumor size and risk of death was captured by the PrimarySizeOnly equation. For breast carcinoma, the model indicated that each positive lymph node contributed approximately 6% extra risk of death, whereas each millimeter of greatest primary tumor dimension contributed approximately 1% risk of death. For melanoma, each positive lymph node contributed approximately 23% risk of death, whereas each millimeter of primary melanoma thickness contributed approximately 8% risk of death. This information was captured by a pair of linked equations, the Size+Nodes method.
CONCLUSIONS: : Both tumor size and the number of positive lymph nodes made independent contributions to the risk of cancer death, as estimated by using the Size+Nodes method. Cancer 2009. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19670458     DOI: 10.1002/cncr.24592

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI.

Authors:  Julian Kirchner; Johannes Grueneisen; Ole Martin; Mark Oehmigen; Harald H Quick; Ann-Kathrin Bittner; Oliver Hoffmann; Marc Ingenwerth; Onofrio Antonio Catalano; Philipp Heusch; Christian Buchbender; Michael Forsting; Gerald Antoch; Ken Herrmann; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-28       Impact factor: 9.236

2.  Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors.

Authors:  Emily C Zabor; Daniel Coit; Jeffrey E Gershenwald; Kelly M McMasters; James S Michaelson; Arnold J Stromberg; Katherine S Panageas
Journal:  Ann Surg Oncol       Date:  2018-02-22       Impact factor: 5.344

3.  Are metastases from metastases clinical relevant? Computer modelling of cancer spread in a case of hepatocellular carcinoma.

Authors:  Anja Bethge; Udo Schumacher; Andreas Wree; Gero Wedemann
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

4.  Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study.

Authors:  Annarita Fanizzi; Domenico Pomarico; Angelo Paradiso; Samantha Bove; Sergio Diotaiuti; Vittorio Didonna; Francesco Giotta; Daniele La Forgia; Agnese Latorre; Maria Irene Pastena; Pasquale Tamborra; Alfredo Zito; Vito Lorusso; Raffaella Massafra
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

5.  Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.

Authors:  Nils Martin Bruckmann; Julian Kirchner; Janna Morawitz; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Andreas Stang; Gerald Antoch; Lino M Sawicki; Christian Buchbender
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

6.  Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms.

Authors:  Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Swetlana Mohrmann; Thomas Gauler; Sarah Theurer; Christina Antke; Irene Esposito; Sonja Kinner; Benedikt M Schaarschmidt; Bernd Kowall; Diana Lütke-Brintrup; Andreas Stang; Anton S Becker; Gerald Antoch; Christian Buchbender
Journal:  Eur J Radiol       Date:  2020-04-24       Impact factor: 4.531

7.  Hyperlipidemia and hyper glycaemia in Breast Cancer Patients is related to disease stage.

Authors:  Uzma Raza; Mahay Rookh Asif; Asif Bin Rehman; Aminuddin Sheikh
Journal:  Pak J Med Sci       Date:  2018 Jan-Feb       Impact factor: 1.088

8.  Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients.

Authors:  Nils Martin Bruckmann; Lino M Sawicki; Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Wolfgang Fendler; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Frederic Dietzel; Marc Ingenwerth; Benedikt M Schaarschmidt; Yan Li; Bernd Kowall; Andreas Stang; Gerald Antoch; Christian Buchbender
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-24       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.